Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0001511 (Adhesion)
 5,955 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Aspergillus fumigatus, an opportunistic fungal pathogen, infects the human host via inhalation of airborne conidia. Adhesion of fungal conidia, to host cells and extracellular matrix (ECM) components associated with host tissue surfaces, is thought to be the primary step in the pathogenesis and dissemination of infection. To identify novel adhesion proteins (adhesins) of A. fumigatus, we screened its proteome in silico using SPAAN (software program for prediction of adhesins and adhesin-like proteins using neural networks). One of the predicted adhesin-encoding genes with a P(ad) (probability of being adhesin) value >0.9, the gene encoding extracellular thaumatin domain protein (AfCalA), was cloned and expressed in Escherichia coli. Recombinant AfCalAp showed significant binding with laminin and murine lung cells. Anti-AfCalAp antibodies inhibited the binding of AfCalAp to laminin in a dose-dependent manner. Significant binding of anti-AfCalAp antibodies to 2 h swollen conidia suggests the presence of AfCalAp on the conidial surface. AfCalA transcript was not detectable in resting conidia but was detected in conidia incubated with RPMI 1640 medium in the presence and absence of lung epithelial cell line (A539)-derived ECM. Elevated levels of IgE antibodies specific to AfCalAp were observed in the sera of two out of seven patients with allergic bronchopulmonary aspergillosis. The study confirms the relevance of the bioinformatic approach for predicting fungal adhesins and establishes AfCalAp as a novel laminin-binding protein of A. fumigatus.
 ...
PMID:Identification and characterization of a laminin-binding protein of Aspergillus fumigatus: extracellular thaumatin domain protein (AfCalAp). 1942 46

As the pathophysiologic process of asthma has become better defined, new molecular targets for treating asthma have emerged. Resident airway cells, circulating leukocytes, and various cell-derived mediators and cytokines contribute to the inflammatory events of asthma. New therapeutic approaches to moderate to severe asthma currently in clinical development include antibodies to IgE and interleukin-5, a soluble receptor that would sequester interleukin-4, cytokine and chemokine receptor antagonists, and phosphodiesterase type 4 inhibitors. Adhesion molecules, which are involved in the migration of inflammatory cells into lung tissue, are also important targets for new antiasthma therapies. Because of researchers' focus on specific pathologic processes and molecular targets, the adverse effects of new agents may be minimized. Also, the longer duration of action of some of the new agents allows weekly to monthly dosing, which may well enhance patient compliance.
 ...
PMID:Treating asthma in the new millennium. 1966 33


<< Previous 1 2